Clinical Trials Browser

Withdrawn × Topotecan × Clear all

NCT05295589 2023-09-26

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Phase 2 Withdrawn

Platinum-Refractory Fallopian Tube Carcinoma

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Phase 3 Withdrawn

Uterine Cervical Neoplasms

NCT00109798 2017-09-19

Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma

Phase NA Withdrawn

Lymphoma, Central Nervous System Neoplasms

NCT01736800 2017-09-19

Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors

Phase 2 Withdrawn

Brain Neoplasms, Neoplasm Metastasis

NCT00682279 2015-04-17

A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors

Phase 1 Withdrawn

Other solid neoplasm

Advanced Solid Tumors

NCT01795430 2015-01-09

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

Phase NA Withdrawn

Neuroectodermal Tumors, Primitive, Peripheral

NCT00006374 2014-01-15

Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2 Withdrawn

Lung Neoplasms, Small Cell Lung Carcinoma

NCT00084565 2013-07-10

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT00389766 2013-07-10

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

Phase 2 Withdrawn

Neuroblastoma

NCT00334867 2013-06-28

Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma

Phase 3 Withdrawn

Sarcoma, Neuroectodermal Tumors, Primitive, Peripheral